Rhythm Pharmaceuticals, Inc.
RYTM
Rank in Stocks
#3016
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Share Price
$88.37
Last synced: 2026-10-19
Market Cap
$6.08B
Change (1 day)
2.55%
Change (1 year)
-21.37%
Country
US
Trade Rhythm Pharmaceuticals, Inc. (RYTM)
Category
Healthcare
Revenue for Rhythm Pharmaceuticals, Inc. (RYTM)
Revenue in Jun 2026 TTM: $239.92M
According to Rhythm Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $239.92M. In 2023 the company made a revenue of $77.43M an increase over the revenue in the year 2022 that was $23.64M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Rhythm Pharmaceuticals, Inc. from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $239.92M | 84.37% |
| 2024 | $130.13M | 68.06% |
| 2023 | $77.43M | 227.56% |
| 2022 | $23.64M | 649.46% |
| 2021 | $3.15M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 5,161.92% |
US
|
|
| $2.23B | 828.65% |
US
|
|
| $15.74B | 6,462.38% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,409.73% |
NL
|
